Merck & Co., Inc. (NYSE:MRK) Stock Acquired Rep. Lisa C. McClain

Representative Lisa C. McClain (R-Michigan) recently bought shares of Merck & Co., Inc. (NYSE:MRK). In a filing disclosed on August 13th, the Representative disclosed that they had bought between $1,001 and $15,000 in Merck & Co., Inc. stock on June 24th. The trade occurred in the Representative’s “CHARLES SCHWAB BROKERAGE ACCOUNT 924” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Autoliv (NYSE:ALV) on 8/4/2025.
• Sold $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 8/4/2025.
• Sold $1,001 – $15,000 in shares of Applied Materials (NASDAQ:AMAT) on 8/4/2025.
• Sold $1,001 – $15,000 in shares of Arthur J. Gallagher & Co. (NYSE:AJG) on 8/4/2025.
• Sold $1,001 – $15,000 in shares of SAP (NYSE:SAP) on 7/22/2025.
• Purchased $1,001 – $15,000 in shares of XPO (NYSE:XPO) on 7/22/2025.
• Purchased $1,001 – $15,000 in shares of Lithia Motors (NYSE:LAD) on 7/22/2025.
• Sold $1,001 – $15,000 in shares of Sanofi (NASDAQ:SNY) on 7/22/2025.
• Sold $1,001 – $15,000 in shares of Waters (NYSE:WAT) on 7/22/2025.
• Purchased $1,001 – $15,000 in shares of Group 1 Automotive (NYSE:GPI) on 7/22/2025.

Merck & Co., Inc. Stock Performance

Merck & Co., Inc. stock opened at $84.21 on Tuesday. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.69. The firm has a 50-day moving average of $81.28 and a 200-day moving average of $83.21. The firm has a market cap of $210.34 billion, a P/E ratio of 12.98, a P/E/G ratio of 0.89 and a beta of 0.38. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $120.30.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, July 29th. The company reported $2.13 EPS for the quarter, beating analysts’ consensus estimates of $2.03 by $0.10. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%. The business had revenue of $15.81 billion during the quarter, compared to analyst estimates of $15.92 billion. Sell-side analysts expect that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 7th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.81 per share. This represents a $3.24 annualized dividend and a dividend yield of 3.8%. The ex-dividend date of this dividend is Monday, September 15th. Merck & Co., Inc.’s dividend payout ratio is 49.92%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on MRK shares. Morgan Stanley decreased their target price on Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating for the company in a report on Thursday, July 10th. Wall Street Zen downgraded shares of Merck & Co., Inc. from a “strong-buy” rating to a “buy” rating in a research report on Friday, April 25th. Citigroup restated a “neutral” rating and issued a $84.00 price objective (down from $115.00) on shares of Merck & Co., Inc. in a report on Wednesday, May 14th. Wells Fargo & Company dropped their target price on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 30th. Finally, Cantor Fitzgerald cut shares of Merck & Co., Inc. from an “overweight” rating to a “cautious” rating in a research report on Tuesday, May 20th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $107.44.

Institutional Investors Weigh In On Merck & Co., Inc.

Institutional investors have recently modified their holdings of the stock. Geneos Wealth Management Inc. boosted its stake in Merck & Co., Inc. by 50.4% in the 2nd quarter. Geneos Wealth Management Inc. now owns 28,954 shares of the company’s stock worth $2,292,000 after purchasing an additional 9,698 shares in the last quarter. Caxton Associates LLP raised its holdings in Merck & Co., Inc. by 23.3% in the second quarter. Caxton Associates LLP now owns 39,421 shares of the company’s stock worth $3,121,000 after buying an additional 7,458 shares during the last quarter. Wellington Capital Management Inc. bought a new position in shares of Merck & Co., Inc. in the second quarter worth approximately $346,000. Second Line Capital LLC lifted its stake in shares of Merck & Co., Inc. by 13.3% in the second quarter. Second Line Capital LLC now owns 6,078 shares of the company’s stock worth $486,000 after buying an additional 715 shares in the last quarter. Finally, Rexford Capital Inc. purchased a new stake in shares of Merck & Co., Inc. during the second quarter valued at approximately $609,000. 76.07% of the stock is owned by hedge funds and other institutional investors.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About Merck & Co., Inc.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.